IL98237A - Preparation for the treatment of dry eyes - Google Patents

Preparation for the treatment of dry eyes

Info

Publication number: IL98237A
Authority: IL; Israel
Prior art keywords: oil; eye; phospholipid; emulsion; composition
Prior art date: 1990-05-29

Application number

IL9823791A

Other languages

English (en)

Hebrew (he)

Other versions

IL98237A0 (en

Original Assignee

Boston Ocular Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-05-29

Filing date

1991-05-23

Publication date

1996-08-04

1991-05-23 Application filed by Boston Ocular Res filed Critical Boston Ocular Res

1992-06-21 Publication of IL98237A0 publication Critical patent/IL98237A0/xx

1996-08-04 Publication of IL98237A publication Critical patent/IL98237A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 146
208000003556 Dry Eye Syndromes Diseases 0.000 title description 46
206010013774 Dry eye Diseases 0.000 title description 46
150000003904 phospholipids Chemical class 0.000 claims abstract description 85
230000008020 evaporation Effects 0.000 claims abstract description 12
238000001704 evaporation Methods 0.000 claims abstract description 12
239000007764 o/w emulsion Substances 0.000 claims abstract description 6
239000003921 oil Substances 0.000 claims description 149
239000000839 emulsion Substances 0.000 claims description 74
230000015572 biosynthetic process Effects 0.000 claims description 23
239000004094 surface-active agent Substances 0.000 claims description 19
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 10
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 10
229930195733 hydrocarbon Natural products 0.000 claims description 8
239000004215 Carbon black (E152) Substances 0.000 claims description 7
150000002430 hydrocarbons Chemical class 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 4
239000002480 mineral oil Substances 0.000 claims description 4
235000010446 mineral oil Nutrition 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
208000002193 Pain Diseases 0.000 claims description 3
239000000607 artificial tear Substances 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
230000009467 reduction Effects 0.000 claims description 3
239000003814 drug Substances 0.000 claims 2
231100000252 nontoxic Toxicity 0.000 claims 2
230000003000 nontoxic effect Effects 0.000 claims 2
239000004721 Polyphenylene oxide Substances 0.000 claims 1
150000007513 acids Chemical class 0.000 claims 1
208000002925 dental caries Diseases 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
229920000570 polyether Polymers 0.000 claims 1
238000000034 method Methods 0.000 abstract description 25
235000019198 oils Nutrition 0.000 description 129
239000010408 film Substances 0.000 description 97
238000009472 formulation Methods 0.000 description 30
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
230000006872 improvement Effects 0.000 description 20
239000000243 solution Substances 0.000 description 19
150000002632 lipids Chemical class 0.000 description 14
239000000463 material Substances 0.000 description 14
208000024891 symptom Diseases 0.000 description 14
238000007792 addition Methods 0.000 description 12
239000000654 additive Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
239000012071 phase Substances 0.000 description 9
150000001875 compounds Chemical class 0.000 description 8
XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 8
206010047513 Vision blurred Diseases 0.000 description 7
230000004888 barrier function Effects 0.000 description 7
-1 dodecate Chemical compound 0.000 description 7
239000012530 fluid Substances 0.000 description 7
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 7
230000000996 additive effect Effects 0.000 description 6
150000002327 glycerophospholipids Chemical class 0.000 description 6
239000007788 liquid Substances 0.000 description 6
230000008569 process Effects 0.000 description 6
230000002035 prolonged effect Effects 0.000 description 6
230000007480 spreading Effects 0.000 description 6
238000003892 spreading Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
150000001335 aliphatic alkanes Chemical class 0.000 description 5
230000004397 blinking Effects 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
229960001484 edetic acid Drugs 0.000 description 5
210000004175 meibomian gland Anatomy 0.000 description 5
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
239000011521 glass Substances 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
230000001179 pupillary effect Effects 0.000 description 4
230000028327 secretion Effects 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
230000006870 function Effects 0.000 description 3
230000007774 longterm Effects 0.000 description 3
238000005461 lubrication Methods 0.000 description 3
150000003905 phosphatidylinositols Chemical class 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
230000003362 replicative effect Effects 0.000 description 3
239000004334 sorbic acid Substances 0.000 description 3
229940075582 sorbic acid Drugs 0.000 description 3
235000010199 sorbic acid Nutrition 0.000 description 3
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
206010010804 Contact lens intolerance Diseases 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
230000008859 change Effects 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
150000001840 cholesterol esters Chemical class 0.000 description 2
210000000795 conjunctiva Anatomy 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
235000013345 egg yolk Nutrition 0.000 description 2
210000002969 egg yolk Anatomy 0.000 description 2
MMKRHZKQPFCLLS-UHFFFAOYSA-N ethyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OCC MMKRHZKQPFCLLS-UHFFFAOYSA-N 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
150000002321 glycerophosphoglycerophosphoglycerols Chemical class 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
235000014571 nuts Nutrition 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229950008882 polysorbate Drugs 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
229940031439 squalene Drugs 0.000 description 2
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000013589 supplement Substances 0.000 description 2
239000012085 test solution Substances 0.000 description 2
239000010409 thin film Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
HNUQMTZUNUBOLQ-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO HNUQMTZUNUBOLQ-UHFFFAOYSA-N 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
235000003332 Ilex aquifolium Nutrition 0.000 description 1
235000002296 Ilex sandwicensis Nutrition 0.000 description 1
235000002294 Ilex volkensiana Nutrition 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
235000019485 Safflower oil Nutrition 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
125000004442 acylamino group Chemical group 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000030 antiglaucoma agent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
239000010692 aromatic oil Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000002801 charged material Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
235000021384 green leafy vegetables Nutrition 0.000 description 1
230000036541 health Effects 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
239000007970 homogeneous dispersion Substances 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
239000000815 hypotonic solution Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
229940049918 linoleate Drugs 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
JYTMDBGMUIAIQH-ZPHPHTNESA-N palmityl oleate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC JYTMDBGMUIAIQH-ZPHPHTNESA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940067626 phosphatidylinositols Drugs 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
238000009877 rendering Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
239000003813 safflower oil Substances 0.000 description 1
235000005713 safflower oil Nutrition 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
238000006748 scratching Methods 0.000 description 1
230000002393 scratching effect Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229940114926 stearate Drugs 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
238000012956 testing procedure Methods 0.000 description 1
QZZGJDVWLFXDLK-UHFFFAOYSA-M tetracosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC([O-])=O QZZGJDVWLFXDLK-UHFFFAOYSA-M 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
230000008719 thickening Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
239000004034 viscosity adjusting agent Substances 0.000 description 1
238000010792 warming Methods 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Ophthalmology & Optometry (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Cosmetics (AREA)

IL9823791A 1990-05-29 1991-05-23 Preparation for the treatment of dry eyes IL98237A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US52965790A	1990-05-29	1990-05-29
US63821591A	1991-01-07	1991-01-07

Publications (2)

Publication Number	Publication Date
IL98237A0 IL98237A0 (en)	1992-06-21
IL98237A true IL98237A (en)	1996-08-04

Family

ID=27063077

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9823791A IL98237A (en)	1990-05-29	1991-05-23	Preparation for the treatment of dry eyes

Country Status (12)

Country	Link
US (1)	US5294607A (de)
EP (1)	EP0459148B1 (de)
JP (1)	JP3281392B2 (de)
AT (1)	ATE132366T1 (de)
AU (1)	AU648304B2 (de)
CA (1)	CA2043366C (de)
DE (1)	DE69115990T2 (de)
ES (1)	ES2084722T3 (de)
GR (1)	GR3019478T3 (de)
IL (1)	IL98237A (de)
RU (1)	RU2092138C1 (de)
TW (1)	TW200396B (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5364632A (en) *	1989-04-05	1994-11-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Medicinal emulsions
ZA927277B (en) *	1991-10-02	1993-05-19	Boston Ocular Res	Dry eye treatment process and solution.
EP0733918B1 (de) *	1995-03-24	2003-07-30	Ocular Research of Boston, Inc.	Hydrogellinse mit Lipid-Vorbeschichtigung
DE19511322C2 (de)	1995-03-28	1999-09-02	Mann Gerhard Chem Pharm Fab	Sterile Augengele mit einem Gehalt an mittelkettigen Triglyceriden und Verfahren zu deren Herstellung
US5616342A (en) *	1995-04-11	1997-04-01	Pdt, Inc.	Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof
DE19527132A1 (de) *	1995-07-25	1997-01-30	Laevosan Gmbh & Co Kg	Ophthalmologische Ozonschutzzusammensetzung
US5696166A (en) *	1995-10-31	1997-12-09	Yanni; John M.	Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
JPH10218760A (ja) *	1997-02-04	1998-08-18	Nobel Igaku Kenkyusho:Kk	ドライアイ治療用の微量油添加目薬
ZA989513B (en)	1997-10-21	1999-04-21	Alcon Lab Inc	Compositions containing histamine H2 agonists and methods of use in treating dry eye
RU2125427C1 (ru) *	1998-05-27	1999-01-27	Миронова Эмилия Михайловна	Средство для лечения глазных заболеваний - оковидит
EP0982025A1 (de) *	1998-08-28	2000-03-01	Wilhelm Prof. Dr. Stoffel	Künstliche Tränen
AU2183900A (en)	1998-12-24	2000-07-31	Alcon Laboratories, Inc.	Ep4 receptor agonists for treatment of dry eye
AU2183800A (en)	1998-12-24	2000-07-31	Alcon Laboratories, Inc.	Prostaglandin e agonists for treatment of dry eye
JP2002538124A (ja)	1999-03-01	2002-11-12	ヴィスタサイエンティフィックエルエルシー	ムチンを含む眼科用調合物
AUPQ228199A0 (en) *	1999-08-18	1999-09-09	Sly, Anthony William	Ophthalmic fluid
PT1228030E (pt)	1999-11-09	2005-08-31	Alcon Inc	Derivados benzenoidicos do acido 15-hidroxieicosatetraenoico e metodos para a sua utilizacao no tratamento das perturbacoes do olho seco
DE60019322T2 (de)	1999-11-09	2005-09-08	Alcon Inc.	Heteroatomunterbrochene analoge von15-hydroxyeicosatetraensäure und verfahren zu deren verwendung
US6255343B1 (en)	1999-11-09	2001-07-03	Alcon Universal Ltd.	2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
ATE258791T1 (de) *	1999-11-09	2004-02-15	Alcon Inc	Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
US6331644B1 (en)	1999-11-09	2001-12-18	Alcon Universal Ltd.	3-heteroatom substituted and two carbon homologs of 15-HETE and methods of use
WO2001034550A2 (en)	1999-11-09	2001-05-17	Alcon Universal Ltd.	15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
BR0015402A (pt)	1999-11-09	2002-06-25	Alcon Inc	Derivados de ácido 15-hidroxieicosatetraenóico de cadeia Èmega modificada e métodos de seu uso para o tratamento de olho seco
DK1228032T3 (da)	1999-11-09	2004-11-01	Alcon Inc	Præparater, som indeholder hydroxyicosatetraensyrederivater, og fremgangsmåder til anvendelse ved behandling af öjentörhedslidelser
US6803385B2 (en)	1999-11-09	2004-10-12	Alcon, Inc.	Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
DE60007547T2 (de)	1999-11-09	2004-06-17	Alcon, Inc.	15-hydroxyeicosatetraensäure verwandte verbindungen und anwendungsverfahren
KR20020050240A (ko)	1999-11-09	2002-06-26	구이도 콜러, 스테판 바슬러	하이드록시에이코사테트라에노에이트 염, 조성물 및 안구건조증 치료에서의 사용 방법
AU1226001A (en)	1999-11-09	2001-06-06	Alcon Universal Limited	Phospholipids of hydroxyeicosatetraenoic acid-like derivatives
US6458854B2 (en)	1999-11-09	2002-10-01	Alcon Universal Ltd.	Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
US6552084B2 (en)	1999-11-09	2003-04-22	Alcon Universal Ltd.	Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
US6576663B2 (en)	1999-12-22	2003-06-10	Alcon, Inc.	6-Keto prostaglandin F1α and analogs for treating dry eye
US6348508B1 (en)	2000-04-04	2002-02-19	Bausch & Lomb Incorporated	Method for treating dry eye
US7524511B1 (en)	2000-07-12	2009-04-28	Rogue Valley Natural Springs, Inc.	Method and kit for moisturizing the surface of the eye
AU2001273251B2 (en) *	2000-07-12	2005-03-24	Rogue Valley Natural Springs, Inc.	Method and kit for moisturizing the surface of the eye
US20030008853A1 (en) *	2001-05-21	2003-01-09	Alcon, Inc.	Method for treating dry eye disorders
BR0209965A (pt)	2001-05-21	2004-04-06	Alcon Inc	Uso de inibidores de nf-kappab para tratar distúrbios do olho seco
ATE353667T1 (de)	2001-05-21	2007-03-15	Alcon Inc	Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
US6872382B1 (en)	2001-05-21	2005-03-29	Alcon, Inc.	Use of selective PDE IV inhibitors to treat dry eye disorders
US7112588B2 (en) *	2001-05-21	2006-09-26	Alcon, Inc.	Use of proteasome inhibitors to treat dry eye disorders
US6645994B1 (en)	2001-06-01	2003-11-11	Alcon, Inc.	Method of treating dry eye disorders
FR2827190A1 (fr) *	2001-06-22	2003-01-17	Rhodia Chimie Sa	Utilisation d'une huile comprenant un groupement polaire comme aide au depot d'une huile polaire non ionisable
US6750250B1 (en)	2001-07-12	2004-06-15	Alcon, Inc.	11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
DE10141018A1 (de) *	2001-08-22	2003-03-13	Eth Zuerich Eidgenoessische Te	Verwendung von negativ geladenen Phospholipiden, sowie Zusammensetzungen umfassend Phospholipide zur Behandlung des Auges
AR035293A1 (es) *	2001-08-23	2004-05-05	Novartis Ag	Composicion oftalmica.
US20040214754A1 (en) *	2001-10-03	2004-10-28	Ellis Edward J.	Ophthalmic preparation containing glycomacropeptide
US20040220089A1 (en) *	2001-10-03	2004-11-04	Ellis Edward J.	Ophthalmic preparation containing glycoprotein
US20030109508A1 (en) *	2001-10-11	2003-06-12	Alcon, Inc.	Methods for treating dry eye
MXPA04003299A (es) *	2001-10-11	2004-07-23	Alcon Inc	Metodos para tratar la resequedad ocular mediante una combinacion de un esteroide antiinflamatorio y un secretagogo muc-1.
US6656460B2 (en) *	2001-11-01	2003-12-02	Yissum Research Development	Method and composition for dry eye treatment
AU782913B2 (en) *	2001-11-02	2005-09-08	Santen Sas	Method and composition for dry eye treatment
CN100469776C (zh) *	2002-05-17	2009-03-18	奥特拉控股公司	白内障和其它眼病发展的改善
RU2232582C2 (ru) *	2002-07-29	2004-07-20	Уфимский научно-исследовательский институт глазных болезней	Глазная пленка
BR0314603A (pt) *	2002-09-20	2005-07-26	Alcon Inc	Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
AU2003303623A1 (en) *	2002-12-20	2004-07-29	Alcon, Inc.	Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells
US7235556B2 (en)	2003-04-16	2007-06-26	Alcon, Inc.	Methods of treating dry eye disorders
US7825134B2 (en) *	2003-05-19	2010-11-02	Othera Holding, Inc.	Amelioration of cataracts, macular degeneration and other ophthalmic diseases
RU2245137C1 (ru) *	2003-06-18	2005-01-27	Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова	Фармацевтическая композиция для лечения воспалительных процессов вирусной этиологии в глазном яблоке
US20070053861A1 (en) *	2003-09-10	2007-03-08	Senju Pharmaceutical Co., Ltd.	Ophthalmic composition for contact lens
MXPA03011987A (es)	2003-12-19	2005-06-23	Osio Sancho Alberto	Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
WO2005067892A1 (en) *	2004-01-10	2005-07-28	Biolipid, Inc.	Lipid compositions and methods of use
US20050182039A1 (en) *	2004-02-13	2005-08-18	Bausch & Lomb Incorporated	Use of Loteprednol etabonate for the treatment of dry eye
MXPA06010849A (es)	2004-03-25	2007-03-08	Bausch & Lomb	Uso de loteprednol etabonato para el tratamiento del ojo seco.
CN100522147C (zh) *	2004-05-14	2009-08-05	爱尔康公司	5,6,7-三羟基庚酸及其类似物在制备治疗干眼病和眼色素层炎药物中的应用
US7923471B2 (en) *	2004-05-14	2011-04-12	Alcon, Inc.	Method of treating dry eye disorders and uveitis
CN101043884A (zh) *	2004-07-01	2007-09-26	谢彭斯眼科研究公司	用于治疗眼部疾病和病症的组合物和方法
JP5272307B2 (ja) *	2004-07-16	2013-08-28	大正製薬株式会社	水性点眼剤
US7223737B1 (en)	2004-08-13	2007-05-29	Alcon, Inc.	Method of treating dry eye disorders using glycosides
CN101005834A (zh)	2004-08-27	2007-07-25	千寿制药株式会社	干眼症治疗用滴眼液
US20060128803A1 (en) *	2004-12-14	2006-06-15	Alcon, Inc.	Method of treating dry eye disorders using 13(S)-HODE and its analogs
AU2012201476B2 (en) *	2005-01-12	2014-07-17	Ocular Research Of Boston, Inc	Dry eye treatment
US9161905B2 (en) *	2005-01-12	2015-10-20	Ocular Research Of Boston, Inc.	Dry eye treatment
TW200722109A (en) *	2005-03-31	2007-06-16	Bausch & Lomb	Polysaccharide and polyol composition for treating dry eye and related methods of manufacture and methods of use
TWI393567B (zh) *	2005-03-31	2013-04-21	Bausch & Lomb	治療乾眼之組合物及相關之製造方法及使用方法
CA2610152C (en)	2005-06-01	2018-04-10	Edison Pharmaceuticals, Inc.	Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20070004672A1 (en) *	2005-07-01	2007-01-04	Dharmendra Jani	Long lasting alginate dry eye, related methods of manufacture and methods of use
WO2007058935A2 (en) *	2005-11-14	2007-05-24	Bausch & Lomb Incorporated	Ophthalmic composition for dry eye therapy
JP6033177B2 (ja) *	2006-01-13	2016-11-30	大正製薬株式会社	Ｏ／ｗ型エマルション水性点眼剤
JP5748385B2 (ja) *	2006-01-13	2015-07-15	大正製薬株式会社	Ｏ／ｗ型エマルション水性点眼剤
EA019675B1 (ru)	2006-02-22	2014-05-30	Эдисон Фармасьютикалз, Инк.	Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
US7745461B1 (en)	2006-02-27	2010-06-29	Alcon Research, Ltd.	Method of treating dry eye disorders
ES2284398B2 (es)	2006-04-27	2008-12-16	Universidad Complutense De Madrid	Formulacion de vesiculas liposomales en soluciones acuosas con caracteristicas de pelicula lagrimal.
US7691811B2 (en) *	2006-05-25	2010-04-06	Bodor Nicholas S	Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
BRPI0714155A2 (pt) *	2006-07-07	2012-12-25	Bausch & Lomb	composiÇço, e, uso de um agonista do receptor de glucocorticàide dissociado (digra), uma prà-droga do mesmo, ou um sal farmaceuticamente aceitÁvel do mesmo
US20080057022A1 (en) *	2006-08-30	2008-03-06	Erning Xia	Ophthalmic Pharmaceutical Compositions and Uses Thereof
US8138156B2 (en) *	2006-10-18	2012-03-20	Bausch & Lomb Incorporated	Ophthalmic compositions containing diglycine
US20080095754A1 (en) *	2006-10-18	2008-04-24	Burke Susan E	Ophthalmic compositions comprising diglycine
US20080095863A1 (en) *	2006-10-24	2008-04-24	Alcon Manufacturing Ltd.	2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
WO2008052037A2 (en) *	2006-10-24	2008-05-02	Alcon Research, Ltd.	Packaging materials for formulations containing 2-pyrrolidone derivatives
US20080188573A1 (en) *	2007-02-02	2008-08-07	Alcon Research, Ltd.	Use of thy1-fp transgenic mouse for the identification of ophthalmic agents
WO2008120249A1 (en) *	2007-03-30	2008-10-09	Sifi S.P.A.	Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use
CN101674807B (zh) *	2007-05-04	2013-03-20	博士伦公司	用于缓解、改善、治疗或预防干眼症的组合物及其制备和使用方法
KR20100016285A (ko) *	2007-05-07	2010-02-12	보오슈 앤드 롬 인코포레이팃드	안구건조 상태를 감소, 개선, 치료 또는 예방하기 위한 조성물 및 이의 제조 및 사용 방법
WO2008154129A1 (en) *	2007-06-08	2008-12-18	Bausch & Lomb Incorporated	Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
US20090142292A1 (en) *	2007-12-03	2009-06-04	Blackwell Richard I	Method For The Mitigation of Symptoms of Dry Eye
US8629099B2 (en) *	2008-03-25	2014-01-14	Bausch & Lomb Incorporated	Ophthalmic compositions comprising a dipeptide
BRPI0918139B1 (pt)	2008-09-10	2024-04-30	Ptc Therapeutics, Inc	Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos
EP2346513A1 (de) *	2008-09-15	2011-07-27	Bausch & Lomb Incorporated	Zusammensetzungen mit polymeren mit aminozuckereinheiten und verfahren zu ihrer herstellung und verwendung
US8539938B2 (en) *	2009-03-12	2013-09-24	Ford Global Technologies, Llc	Fuel systems and methods for controlling fuel systems in a vehicle with multiple fuel tanks
JP2012525399A (ja)	2009-04-28	2012-10-22	エジソンファーマシューティカルズ，インコーポレイテッド	トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療
TWI478730B (zh) *	2009-12-03	2015-04-01	Alcon Res Ltd	眼科乳劑
US8658614B2 (en)	2010-08-13	2014-02-25	The University of Texas Health Science Center	Aptamer-containing compositions and methods for targeting E-selectin
US9161531B2 (en)	2011-02-23	2015-10-20	Donald R. Korb	High alcohol content sanitizer
US8859525B2 (en)	2011-07-19	2014-10-14	Bausch & Lomb Incorporated	Pharmaceutical compositions comprising mushroom-based polysaccharides and uses thereof
EP2758031A1 (de)	2011-09-22	2014-07-30	Bausch & Lomb Incorporated	Ophthalmische gelzusammensetzungen
US8324171B1 (en)	2012-02-06	2012-12-04	Bausch & Lomb Incorporated	Ophthalmic compositions containing diglycine
US8664180B2 (en)	2012-02-06	2014-03-04	Bausch & Lomb Incorporated	Ophthalmic compositions containing diglycine
US9278132B2 (en)	2012-02-13	2016-03-08	Bausch & Lomb Incorporated	Ophthalmic pharmaceutical compositions and methods of making and using same
EP2816996B1 (de)	2012-02-24	2016-10-05	Bausch & Lomb Incorporated	Ophthalmische zusammensetzungen mit alkoxylierten natürlichen wachsen
JP6016465B2 (ja) *	2012-06-12	2016-10-26	ロート製薬株式会社	ビタミンａ類を含有する水性組成物
ES2994608T3 (en)	2012-08-10	2025-01-27	Osio Corp D/B/A Yolia Health	Contact lens use in the treatment of an ophthalmologic condition
PL2948196T3 (pl)	2013-01-24	2018-01-31	Bausch & Lomb	Poli(azotowane/aminowane) pochodne naturalnego wosku lub jego alkoksylowana pochodna i kompozycje okulistyczne
AU2015229452B2 (en)	2014-03-12	2021-07-15	University Of Virginia Patent Foundation	Compositions and methods for treating eye infections and disease
US9505709B2 (en)	2014-05-05	2016-11-29	Thetis Pharmaceuticals Llc	Compositions and methods relating to ionic salts of peptides
KR20170023061A (ko)	2014-06-18	2017-03-02	테티스 파마수티컬스 엘엘씨	활성제의 미네랄 아미노산 복합체
WO2017079734A1 (en)	2015-11-05	2017-05-11	University Of Louisville Research Foundation, Inc.	Local and regional anesthesia and analgesia
CN113024369A (zh)	2015-12-17	2021-06-25	Ptc医疗公司	用于治疗氧化应急障碍的化合物
CA3026264A1 (en)	2016-06-03	2017-12-07	Thetis Pharmaceuticals Llc	Compositions and methods relating to salts of specialized pro-resolving mediators
US9981041B2 (en)	2016-08-23	2018-05-29	Ira Jason Salzman	Ophthalmic lubricating spray
US12233017B2 (en)	2016-10-14	2025-02-25	Olympic Ophthalmics, Inc.	Quiet handheld devices and methods for treatment of disorders
US20180296390A1 (en) *	2017-04-18	2018-10-18	David Hoare	Apparatus and method for treating a number of eye conditions of a user including dry eye syndrome and/or burns to the eyes
TWI884130B (zh)	2018-02-21	2025-05-21	瑞士商愛爾康公司	基於脂質的眼用乳劑
US11141348B2 (en)	2018-02-26	2021-10-12	Olympic Ophthalmics, Inc.	Treatment methods using handheld devices for disorders
US11278493B2 (en)	2018-12-10	2022-03-22	EternaTear, Inc.	Ophthalmic formulations providing durable ocular lubrication
US11679078B1 (en)	2022-03-08	2023-06-20	EternaTear, Inc.	Ophthalmic formulations and related methods
US11471475B1 (en)	2022-03-08	2022-10-18	Ralph P. Stone	Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4677099A (en) *	1981-09-04	1987-06-30	Yeda Research And Development Co., Ltd.	Medical processes employing a novel lipid fraction
US4421748A (en) *	1982-07-13	1983-12-20	Trager Seymour F	Artificial tear aid
WO1988000824A1 (en) *	1986-07-28	1988-02-11	Liposome Technology, Inc.	Liposomes with enhanced retention on mucosal tissue
US4839175A (en) *	1986-07-28	1989-06-13	Liposome Technology, Inc.	Liposomes with enhanced retention on mucosal tissue
US4804539A (en) *	1986-07-28	1989-02-14	Liposome Technology, Inc.	Ophthalmic liposomes
US4818537A (en) *	1986-10-21	1989-04-04	Liposome Technology, Inc.	Liposome composition for treating dry eye
US4914088A (en) *	1987-04-02	1990-04-03	Thomas Glonek	Dry eye treatment solution and method
US4866049A (en) *	1987-08-10	1989-09-12	Spectra Pharmaceutical Services, Inc.	Ophthalmic compositionn and method of using same
AU614465B2 (en) *	1989-04-05	1991-08-29	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Medicinal emulsions

1991
- 1991-04-25 EP EP91106698A patent/EP0459148B1/de not_active Expired - Lifetime
- 1991-04-25 ES ES91106698T patent/ES2084722T3/es not_active Expired - Lifetime
- 1991-04-25 DE DE69115990T patent/DE69115990T2/de not_active Expired - Lifetime
- 1991-04-25 AT AT91106698T patent/ATE132366T1/de not_active IP Right Cessation
- 1991-04-29 AU AU76191/91A patent/AU648304B2/en not_active Expired
- 1991-05-23 IL IL9823791A patent/IL98237A/en not_active IP Right Cessation
- 1991-05-28 CA CA002043366A patent/CA2043366C/en not_active Expired - Lifetime
- 1991-05-28 RU SU914895511A patent/RU2092138C1/ru active
- 1991-05-29 JP JP22662991A patent/JP3281392B2/ja not_active Expired - Lifetime
- 1991-06-24 TW TW080104892A patent/TW200396B/zh active
1992
- 1992-06-09 US US07/898,375 patent/US5294607A/en not_active Expired - Lifetime
1996
- 1996-04-02 GR GR960400865T patent/GR3019478T3/el unknown

Also Published As

Publication number	Publication date
RU2092138C1 (ru)	1997-10-10
JPH04279525A (ja)	1992-10-05
DE69115990T2 (de)	1996-05-30
TW200396B (de)	1993-02-21
ES2084722T3 (es)	1996-05-16
US5294607A (en)	1994-03-15
AU7619191A (en)	1992-08-06
JP3281392B2 (ja)	2002-05-13
CA2043366C (en)	1999-01-05
EP0459148A2 (de)	1991-12-04
EP0459148A3 (en)	1992-10-14
ATE132366T1 (de)	1996-01-15
DE69115990D1 (de)	1996-02-15
CA2043366A1 (en)	1991-11-30
GR3019478T3 (en)	1996-07-31
EP0459148B1 (de)	1996-01-03
IL98237A0 (en)	1992-06-21
AU648304B2 (en)	1994-04-21

Legal Events

Date	Code	Title
1997-01-10	FF	Patent granted
1997-06-10	KB	Patent renewed
1997-09-30	KB	Patent renewed
2001-07-24	KB	Patent renewed
2009-12-24	KB	Patent renewed
2012-02-29	EXP	Patent expired

Publication	Publication Date	Title
EP0459148B1 (de)	1996-01-03	Zusammensetzung zur Behandlung von Dry Eye Erkrankungen
US5578586A (en)	1996-11-26	Dry eye treatment process and solution
US5278151A (en)	1994-01-11	Dry eye treatment solution
US5371108A (en)	1994-12-06	Dry eye treatment process and solution
EP0312814B1 (de)	1992-09-09	Lösung zur Behandlung von "Dry-Eye"-Erkrankungen
US9044388B2 (en)	2015-06-02	Dry eye treatment
EP0733918B1 (de)	2003-07-30	Hydrogellinse mit Lipid-Vorbeschichtigung
KR20180059823A (ko)	2018-06-05	부분불소화 화합물
CA2464243C (en)	2010-01-19	Method and composition for dry eye treatment
US20070082017A1 (en)	2007-04-12	Lipid compositions and methods of use
JP2024119872A (ja)	2024-09-03	長続きする眼の潤滑をもたらす眼用配合物
JP2021513515A (ja)	2021-05-27	脂質ベースの眼科用エマルジョン
JPH0249733A (ja)	1990-02-20	シクロスポリン製剤
AU2012201476B2 (en)	2014-07-17	Dry eye treatment
Emulsions	1993	Benita et al.